Greater Glasgow and Clyde Medicines

This post summarises the latest NHS Greater Glasgow and Clyde decisions relating to new medicines assessed by SMC and considered by the Area Drug and Therapeutics Committee (ADTC) and uses a nationally developed format specifically aimed for patients and the public.

For full details of the medicines included in this post that are available for use, including any restrictions on prescribing, please see the relevant entry in the GGC Formulary

https://www.choiceandmedication.org/nhs24/   Choice and medication is a free resource hosted within NHS Inform for use in NHS Scotland that provides u...

MHRA Drug Safety Update April 2023

In patients weighing less than 120kg, apixaban is the DOAC of choice for the treatment of venous thromboembolism (VTE) and edoxaban is the DOAC of choice for stroke prevention secondary to non-valvular atrial fibrillation (AF) in NHSGGC.

For patients weighing 120-150kg, apixaban is the DOAC of choice in NHSGGC for treatment of VTE and for stroke prevention secondary to non-valvular AF

Guideline News March 2023

This month’s Blog highlights a number of issues around how to use the system safely and most effectively.

Part 2 – Safe inpatient prescribing

This blog is the second in a series outlining risks relating to insulin prescribing and administration for adults in hospital, and at discharge and aims to provide good practice points to minimise these risks.

MHRA Drug Safety Update for March 2023

Key Medicine Shortages – March 2023